IL-4 analogues with site-specific chemical modification at position 121 inhibit IL-4 and IL-13 biological activities

Bioconjugate Chemistry

Volumn 25, Issue 1, 2014, Pages 52-62

  Duppatla, Viswanadham ^a   Gjorgjevikj, Maja ^a   Schmitz, Werner ^a   Hermanns, Heike M ^c   Schäfer, Carmen M ^c   Kottmair, Mathias ^b   Müller, Thomas ^b   Sebald, Walter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BINDING ENERGY; BIOACTIVITY; CELL CULTURE; CELL SIGNALING; CELLS; CHAINS; SULFUR COMPOUNDS;

BINDING AFFINITIES; CHEMICALLY MODIFIED; ECTODOMAIN; HIGH AFFINITY; MALEIMIDES; MUTEINS; RECEPTOR COMPLEX; REFOLDING; SITE-SPECIFIC; THIOL COMPOUNDS;

CHEMICAL MODIFICATION;

CYSTEINE; DISULFIDE; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA1; INTERLEUKIN 4; MALEIMIDE; MALEIMIDE DERIVATIVE; THIOL DERIVATIVE; THIOL GROUP;

ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CONJUGATE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PROTEIN INTERACTION; PROTEIN MODIFICATION; RECEPTOR BINDING; SURFACE PLASMON RESONANCE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; JURKAT CELL LINE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HUMANS; INTERLEUKIN-13; INTERLEUKIN-4; JURKAT CELLS; MODELS, MOLECULAR; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84892742244     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400307k     Document Type: Article

References (41)

1. Hage, T., Sebald, W., and Reinemer, P. (1999) Crystal structure of the interleukin-4/receptor alpha chain complex reveals a mosaic binding interface Cell 97, 271-281
2. LaPorte, S. L., Juo, Z. S., Vaclavikova, J., Colf, L. A., Qi, X., Heller, N. M., Keegan, A. D., and Garcia, K. C. (2008) Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system Cell 132, 259-272
3. Sebald, W., Nickel, J., Zhang, J. L., and Mueller, T. D. (2010) Molecular basis of cytokine signalling - theme and variations FEBS J. 277, 106-118
4. Junttila, I. S., Mizukami, K., Dickensheets, H., Meier-Schellersheim, M., Yamane, H., Donnelly, R. P., and Paul, W. E. (2008) Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Ralpha, IL-13Ralpha1, and gammac regulates relative cytokine sensitivity J. Exp. Med. 205, 2595-2608
5. Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., and Paul, W. E. (1999) The IL-4 receptor: signaling mechanisms and biologic functions Annu. Rev. Immunol. 17, 701-738
6. Coffman, R. L. (2013) Converging discoveries: the first reports of IL-4 J. Immunol. 190, 847-848
7. Liang, H. E., Reinhardt, R. L., Bando, J. K., Sullivan, B. M., Ho, I. C., and Locksley, R. M. (2012) Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity Nat. Immunol. 13, 58-66
8. Paul, W. E. and Zhu, J. (2010) How are T(H)2-type immune responses initiated and amplified? Nat. Rev. Immunol. 10, 225-235
9. Ramalingam, T. R., Pesce, J. T., Sheikh, F., Cheever, A. W., Mentink-Kane, M. M., Wilson, M. S., Stevens, S., Valenzuela, D. M., Murphy, A. J., Yancopoulos, G. D., Urban, J. F., Jr., Donnelly, R. P., and Wynn, T. A. (2008) Unique functions of the type II interleukin 4 receptor identified in mice lacking the interleukin 13 receptor alpha1 chain Nat. Immunol. 9, 25-33
10. Brandt, E. B. and Sivaprasad, U. (2011) Th2 cytokines and atopic dermatitis J. Clin. Cell. Immunol. 2, 110-120
11. Ingram, J. L. and Kraft, M. (2012) IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies J. Allergy Clin. Immunol. 130, 829-842 quiz 843-844.
12. Kuperman, D. A. and Schleimer, R. P. (2008) Interleukin-4, interleukin-13, signal transducer and activator of transcription factor 6, and allergic asthma Curr. Mol. Med. 8, 384-392
13. Arron, J. R., Scheerens, H., and Matthews, J. G. (2013) Redefining approaches to asthma: developing targeted biologic therapies Adv. Pharmacol. 66, 1-49
14. Li, Z., Jiang, J., Wang, Z., Zhang, J., Xiao, M., Wang, C., Lu, Y., and Qin, Z. (2008) Endogenous interleukin-4 promotes tumor development by increasing tumor cell resistance to apoptosis Cancer Res. 68, 8687-8694
15. Di Stefano, A. B., Iovino, F., Lombardo, Y., Eterno, V., Hoger, T., Dieli, F., Stassi, G., and Todaro, M. (2010) Survivin is regulated by interleukin-4 in colon cancer stem cells J. Cell. Physiol. 225, 555-561
16. Smith, L. J., Redfield, C., Smith, R. A., Dobson, C. M., Clore, G. M., Gronenborn, A. M., Walter, M. R., Naganbushan, T. L., and Wlodawer, A. (1994) Comparison of four independently determined structures of human recombinant interleukin-4 Nat. Struct. Biol. 1, 301-310
17. Kelly-Welch, A. E., Hanson, E. M., Boothby, M. R., and Keegan, A. D. (2003) Interleukin-4 and interleukin-13 signaling connections maps Science 300, 1527-1528
18. Mueller, T. D., Zhang, J. L., Sebald, W., and Duschl, A. (2002) Structure, binding, and antagonists in the IL-4/IL-13 receptor system Biochim. Biophys. Acta 1592, 237-250
19. Kruse, N., Tony, H. P., and Sebald, W. (1992) Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement EMBO J. 11, 3237-3244
20. Tony, H. P., Shen, B. J., Reusch, P., and Sebald, W. (1994) Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency Eur. J. Biochem. 225, 659-665
21. Tomkinson, A., Tepper, J., Morton, M., Bowden, A., Stevens, L., Harris, P., Lindell, D., Fitch, N., Gundel, R., and Getz, E. B. (2010) Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma Allergy 65, 69-77
22. Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B., and Longphre, M. (2007) Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies Lancet 370, 1422-1431
23. Kruse, N., Shen, B. J., Arnold, S., Tony, H. P., Muller, T., and Sebald, W. (1993) Two distinct functional sites of human interleukin 4 are identified by variants impaired in either receptor binding or receptor activation EMBO J. 12, 5121-5129
24. Kreitman, R. J., Puri, R. K., Leland, P., Lee, B., and Pastan, I. (1994) Site-specific conjugation to interleukin 4 containing mutated cysteine residues produces interleukin 4-toxin conjugates with improved binding and activity Biochemistry 33, 11637-11644
25. Pan, C., Roczniak, S., Greve, J. M., Yung, S. L., Longphre, M., Wong, T. M., and Tomkinson, A. (2008) Modified IL-4 Mutein Receptor Antagonists, United States Patent, US 7,404,957 B2.
26. Duppatla, V., Gjorgjevikj, M., Schmitz, W., Kottmair, M., Mueller, T. D., and Sebald, W. (2012) Enzymatic deglutathionylation to generate interleukin-4 cysteine muteins with free thiol Bioconjugate Chem. 23, 1396-1405
27. Shen, B. J., Hage, T., and Sebald, W. (1996) Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor alpha chain interaction. A biosensor study employing recombinant interleukin-4-binding protein Eur. J. Biochem. 240, 252-261
28. Drechsler, J., Grotzinger, J., and Hermanns, H. M. (2012) Characterization of the rat oncostatin M receptor complex which resembles the human, but differs from the murine cytokine receptor PLoS One 7, e43155
29. Letzelter, F., Wang, Y., and Sebald, W. (1998) The interleukin-4 site-2 epitope determining binding of the common receptor gamma chain Eur. J. Biochem. 257, 11-20
30. Kioi, M., Kawakami, K., and Puri, R. K. (2004) Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R Cell. Immunol. 229, 41-51
31. Park, L. S., Friend, D., Sassenfeld, H. M., and Urdal, D. L. (1987) Characterization of the human B cell stimulatory factor 1 receptor J. Exp. Med. 166, 476-488
32. Shanafelt, A. B., Forte, C. P., Kasper, J. J., Sanchez-Pescador, L., Wetzel, M., Gundel, R., and Greve, J. M. (1998) An immune cell-selective interleukin 4 agonist Proc. Natl. Acad. Sci. U.S.A. 95, 9454-9458
33. Kioi, M., Kawakami, K., and Puri, R. K. (2004) Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R Cell. Immunol. 229, 41-51
34. Letzelter, F., Wang, Y., and Sebald, W. (1998) The interleukin-4 site-2 epitope determining binding of the common receptor gamma chain Eur. J. Biochem. 257, 11-20
35. Junttila, I. S., Creusot, R. J., Moraga, I., Bates, D. L., Wong, M. T., Alonso, M. N., Suhoski, M. M., Lupardus, P., Meier-Schellersheim, M., Engleman, E. G., Utz, P. J., Fathman, C. G., Paul, W. E., and Garcia, K. C. (2012) Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines Nat. Chem. Biol. 8, 990-998
36. Piehler, J., Thomas, C., Garcia, K. C., and Schreiber, G. (2012) Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation Immunol. Rev. 250, 317-334
37. Ring, A. M., Lin, J. X., Feng, D., Mitra, S., Rickert, M., Bowman, G. R., Pande, V. S., Li, P., Moraga, I., Spolski, R., Ozkan, E., Leonard, W. J., and Garcia, K. C. (2012) Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15 Nat. Immunol. 13, 1187-1195
38. Kang, L., Bondensgaard, K., Li, T., Hartmann, R., and Hjorth, S. A. (2010) Rational design of interleukin-21 antagonist through selective elimination of the gammaC binding epitope J. Biol. Chem. 285, 12223-12231
39. Walsh, S. T. (2012) Structural insights into the common gamma-chain family of cytokines and receptors from the interleukin-7 pathway Immunol. Rev. 250, 303-316
40. Bailon, P. and Won, C. Y. (2009) PEG-modified biopharmaceuticals Expert Opin. Drug Delivery 6, 1-16
41. Gefen, T., Vaya, J., Khatib, S., Harkevich, N., Artoul, F., Heller, E. D., Pitcovski, J., and Aizenshtein, E. (2013) The impact of PEGylation on protein immunogenicity Int. Immunopharmacol. 15, 254-259